Some peptides are legal, some are not, and it depends on the molecule and the route. FDA-approved peptides such as semaglutide and tesamorelin are legal with a prescription. Unapproved peptides such as BPC-157 cannot be sold for human use, and as of October 2026 no pharmacy may lawfully compound BPC-157, despite a July 2026 advisory vote in its favor.[2][5]
“Are peptides legal?” sounds like a yes-or-no question, but the honest answer is that it depends entirely on which peptide and how you obtain it. The same word covers an FDA-approved prescription drug, a pharmacy-compounded preparation, and a vial labeled “research use only” shipped from an anonymous website. Those three things sit in very different places under U.S. law. This page maps that spectrum as clearly and accurately as we can. It is general information about regulatory status, not legal advice — if you have a specific legal question, talk to a qualified attorney rather than relying on an article.
Which peptides are legal with a prescription?
At the most clearly-legal end of the spectrum, a number of peptides are approved drugs with full FDA review behind them. Tesamorelin (Egrifta) is an approved growth-hormone–releasing analog; the GLP-1 receptor agonist semaglutide is an approved peptide drug used at large scale; bremelanotide (Vyleesi) is another approved injectable peptide. For these, the legality question has a simple answer: they are legal to possess and use when a licensed clinician prescribes them for you and a pharmacy dispenses them. They are manufactured under current Good Manufacturing Practice, so identity, purity, and the actual dose per unit are verified. This is the same framework that governs any prescription medicine.
Many popular “research peptides” are not FDA-approved
Most of the peptides people actually search for — BPC-157, TB-500, and many others — have not been approved by the FDA for any human use. Because they are unapproved, they cannot be sold as drugs for human consumption. The workaround the market uses is to sell them labeled “for research use only” or “not for human consumption.” That label is a legal framing, not a description of the buyer’s intent: it lets a vendor sidestep the rules that apply to drugs while implicitly selling a product everyone understands is destined for human use, often with dosing guidance a click away. This is the heart of the gray market, and it is exactly why we steer readers toward the prescription routes in our guide on where to get peptides safely. The research-use framing does not make the underlying activity safe, and it does not make selling an unapproved drug for human use lawful.
Can a pharmacy legally compound BPC-157?
There is also a more specific regulatory development worth understanding, because it is widely misrepresented in marketing and it changed materially in 2026. A licensed pharmacy can legally compound some medicines — preparing them for an individual patient against a prescription — but it cannot compound from just any ingredient. The FDA maintains category lists for the bulk drug substances that pharmacies nominate for use in compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.[1] Substances the agency has identified as posing significant safety risks are placed into Category 2; substances lawfully usable in compounding must instead appear on the 503A Bulks List.
Around 2023, the FDA sorted several popular peptides — BPC-157 among them — into Category 2, the bucket reserved for substances it judges too risky to compound while the data gaps remain.[2] That classification mattered because it removed the one narrow on-ramp by which an unapproved peptide could otherwise reach a patient lawfully: a pharmacy cannot compound from a Category 2 bulk substance.
That specific fact changed in 2026. After HHS Secretary Robert F. Kennedy Jr. said in February 2026 that most Category 2 peptides should be reconsidered, the nominations for BPC-157 and 16 other substances — including TB-500, thymosin alpha-1, CJC-1295, MOTS-c and GHK-Cu for injection — were withdrawn, and the FDA moved them off Category 2 onto a separate “nominated but withdrawn” list (the FDA page is dated April 22, 2026).[2] Not every peptide moved: ipamorelin remains in Category 2 for outsourcing facilities (503B), and kisspeptin-10 remains in Category 2 for pharmacy compounding (503A). Leaving Category 2 is not, by itself, approval to compound: a substance still needs to reach the 503A Bulks List through a USP monograph, status as a component of an FDA-approved drug, or a formal bulks-list addition. On July 23–24, 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 (8–6, with one abstention), TB-500, KPV and MOTS-c to the 503A Bulks List, against the written recommendation of FDA staff.[5][7] Those votes are advisory, not binding, and the FDA still has to complete formal rulemaking before any pharmacy may lawfully compound these peptides; as of October 2026 we found no final FDA action. BPC-157 therefore sits in a regulatory gray zone: no longer listed as a significant safety risk, but not yet a lawfully compoundable substance either. (For how that translates into vetting an actual supplier, see our guide on where to get peptides safely; for why the efficacy claims also outrun the human evidence, see the BPC-157 evidence review.) Because this status is actively moving through FDA rulemaking, the authoritative answer for any given molecule is always its current entry on FDA.gov, not a snapshot from any single article — including this one.
Are peptides controlled substances?
A common misconception is that “not a controlled substance” means “legal to sell.” Most research peptides are not scheduled controlled substances under the Controlled Substances Act, so simple possession is not the felony-level issue that, say, possessing a scheduled narcotic would be. But the relevant law here is drug law, not drug-scheduling law. Under the Federal Food, Drug, and Cosmetic Act, it is illegal to market or sell an unapproved new drug for human use, and to introduce a misbranded or adulterated drug into commerce.[3] That is the legal exposure the “research use only” disclaimer is designed to dance around. The absence of DEA scheduling does not convert an unapproved drug into a lawful consumer product, and it says nothing at all about whether the product is safe or accurately labeled.
A separate rulebook: banned in sport
Legality under civil law is one question; eligibility to compete is a completely different one, governed by sport authorities rather than the government. The World Anti-Doping Agency (WADA) publishes an annual Prohibited List, and many peptides — growth-hormone secretagogues, GHRH analogs, and various peptide hormones and growth factors among them — fall under banned classes for athletes subject to anti-doping rules.[4] A substance can be perfectly legal to possess yet still cost an athlete a sanction if it turns up in a doping test. We cover that overlap in detail in our companion guide on banned peptides and WADA. If you compete under any anti-doping code, the Prohibited List — not a vendor’s reassurance — is the document that matters.
The personal-use and import gray zone
What about ordering for yourself? This is genuinely a gray area rather than a settled rule. The FDA has discretion over personal importation of unapproved drugs, and that discretion is exercised case by case rather than guaranteeing safe passage; shipments of unapproved drugs can be detained or refused at the border. “People do it and nothing happens” is not the same as “it is legal,” and a product’s research-use label does not protect the buyer from a misbranded, contaminated, or simply inaccurate vial. Because this corner of the law is unsettled and fact-specific, it is precisely where general information stops being useful and a qualified attorney’s advice begins.
The honest bottom line
“Are peptides legal?” has no single answer because the word spans a regulatory spectrum. An FDA-approved peptide drug is legal with a prescription. Many of the most-hyped research peptides are unapproved and are sold under a “research use only” framing that sidesteps, rather than satisfies, drug law. The FDA placed several, including BPC-157, into a compounding category reserved for substances it judges to pose significant safety risks around 2023 — and in 2026 BPC-157 left that category and, via an advisory-committee vote, moved a step toward (but not yet into) lawful compounding.[2] Most peptides are not DEA-scheduled, but selling an unapproved drug for human use remains illegal,[3] and sport authorities ban many peptides outright regardless of civil legality — BPC-157 has been prohibited by name on the WADA list since 2022.[4][6] None of that is legal advice; it is a map of how the rules are structured so you can ask better questions. The clearest takeaway is the one that runs through all of our coverage: the legitimate, lowest-risk route to any peptide that has one runs through a licensed clinician and pharmacy, not a checkout button.
